Weight Loss7 min read

Oral Wegovy: Why More Men Are Choosing the Pill Over Injections

The Wegovy pill launched January 2026 at $149/month. No needles. No refrigeration. Same weight loss. Here's why it's becoming the preferred choice for men.

Weight loss: 16.6% with full adherence (OASIS 4 trial)

Cost: $149/month self-pay (cheapest brand-name GLP-1)

Dosing: One pill daily, empty stomach, 30 min before food

No refrigeration required

Why Men Are Making the Switch

Surveys consistently show that needle aversion keeps a meaningful percentage of men from starting GLP-1 treatment. The oral option removes that barrier entirely. Beyond needles, men cite three main reasons for preferring the pill:

How It Compares

Oral WegovyInjectable WegovyWegovy HD
Dose25mg daily2.4mg weekly7.2mg weekly
Weight loss16.6%~15%20.7%
Self-pay$149/mo$349/moTBD
NeedlesNoneYesYes
RefrigerationNoYesYes

Sesame Care · brand-name Rx

Ask About Oral Wegovy →

Prescribes FDA-approved brand-name medications. Paid link

The Empty Stomach Rule

The one trade-off: oral Wegovy must be taken on an empty stomach with a small amount of water, then you wait 30 minutes before eating or taking other medications. Most men handle this by taking it immediately after waking, then going about their morning routine before breakfast.

Compounded Injectable Alternatives

If you prefer the once-weekly convenience of injections at a lower price point, compounded semaglutide remains available through telehealth providers:

Oak Health Compounded

$130/mo sema

Check Eligibility → Paid link

Compounded medications are not FDA-approved.

Found Health Compounded

from $129/mo

Check Eligibility → Paid link

Compounded medications are not FDA-approved.

The Bottom Line

Oral Wegovy is the most accessible GLP-1 option ever launched — $149/month, no needles, no fridge, FDA-approved. For men who've been on the fence about starting treatment, the barriers are essentially gone. The only real trade-off is daily dosing with a 30-minute fasting window versus once-weekly injection convenience.

Sources

  1. OASIS 4 trial, oral semaglutide 25mg, NEJM 2025
  2. Novo Nordisk press release, December 22, 2025
  3. ABC News, FDA approves Wegovy pill, December 2025

You May Also Like